MX2023003863A - Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped. - Google Patents
Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped.Info
- Publication number
- MX2023003863A MX2023003863A MX2023003863A MX2023003863A MX2023003863A MX 2023003863 A MX2023003863 A MX 2023003863A MX 2023003863 A MX2023003863 A MX 2023003863A MX 2023003863 A MX2023003863 A MX 2023003863A MX 2023003863 A MX2023003863 A MX 2023003863A
- Authority
- MX
- Mexico
- Prior art keywords
- host cell
- cell protein
- protein content
- methods
- antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000011091 antibody purification Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere a métodos para reducir el contenido de proteínas de la célula huésped en una preparación de anticuerpo producido de forma recombinante en una célula huésped en el proceso de fabricación de anticuerpos destinados a la administración a un paciente. Los métodos descritos se pueden realizar para preparar preparaciones de anticuerpos terapéuticos que tengan proteínas de la célula huésped reducidas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063086915P | 2020-10-02 | 2020-10-02 | |
PCT/US2021/053407 WO2022072934A1 (en) | 2020-10-02 | 2021-10-04 | Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003863A true MX2023003863A (es) | 2023-04-14 |
Family
ID=78621988
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003836A MX2023003836A (es) | 2020-10-02 | 2021-10-04 | Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas. |
MX2023003863A MX2023003863A (es) | 2020-10-02 | 2021-10-04 | Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003836A MX2023003836A (es) | 2020-10-02 | 2021-10-04 | Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20230374063A1 (es) |
EP (2) | EP4222160A1 (es) |
JP (2) | JP2023544399A (es) |
KR (2) | KR20230078748A (es) |
CN (2) | CN116348486A (es) |
AR (1) | AR123688A1 (es) |
AU (2) | AU2021355521A1 (es) |
BR (1) | BR112023004871A2 (es) |
CA (2) | CA3192910A1 (es) |
CL (1) | CL2023000961A1 (es) |
CO (1) | CO2023004265A2 (es) |
EC (1) | ECSP23024034A (es) |
IL (2) | IL301572A (es) |
MX (2) | MX2023003836A (es) |
PE (1) | PE20231507A1 (es) |
TW (1) | TW202229307A (es) |
WO (2) | WO2022072919A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10213526B2 (en) | 2014-03-21 | 2019-02-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5808249B2 (ja) * | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
WO2012136552A1 (en) * | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
US10941178B2 (en) * | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
JP7116256B1 (ja) * | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗sars-cov-2-スパイク糖タンパク質抗体および抗原結合断片 |
-
2021
- 2021-10-04 IL IL301572A patent/IL301572A/en unknown
- 2021-10-04 JP JP2023520389A patent/JP2023544399A/ja active Pending
- 2021-10-04 MX MX2023003836A patent/MX2023003836A/es unknown
- 2021-10-04 AU AU2021355521A patent/AU2021355521A1/en active Pending
- 2021-10-04 EP EP21807337.7A patent/EP4222160A1/en active Pending
- 2021-10-04 AU AU2021355518A patent/AU2021355518A1/en active Pending
- 2021-10-04 IL IL301584A patent/IL301584A/en unknown
- 2021-10-04 AR ARP210102747A patent/AR123688A1/es unknown
- 2021-10-04 TW TW110136856A patent/TW202229307A/zh unknown
- 2021-10-04 CN CN202180067683.0A patent/CN116348486A/zh active Pending
- 2021-10-04 PE PE2023001345A patent/PE20231507A1/es unknown
- 2021-10-04 BR BR112023004871A patent/BR112023004871A2/pt unknown
- 2021-10-04 KR KR1020237014350A patent/KR20230078748A/ko active Search and Examination
- 2021-10-04 JP JP2023520349A patent/JP2023545019A/ja active Pending
- 2021-10-04 CN CN202180081449.3A patent/CN116547292A/zh active Pending
- 2021-10-04 US US18/247,084 patent/US20230374063A1/en active Pending
- 2021-10-04 WO PCT/US2021/053318 patent/WO2022072919A1/en unknown
- 2021-10-04 WO PCT/US2021/053407 patent/WO2022072934A1/en active Application Filing
- 2021-10-04 CA CA3192910A patent/CA3192910A1/en active Pending
- 2021-10-04 CA CA3193722A patent/CA3193722A1/en active Pending
- 2021-10-04 US US18/247,198 patent/US20230406914A1/en active Pending
- 2021-10-04 MX MX2023003863A patent/MX2023003863A/es unknown
- 2021-10-04 EP EP21807334.4A patent/EP4222159A1/en active Pending
- 2021-10-04 KR KR1020237011095A patent/KR20230061462A/ko unknown
-
2023
- 2023-03-31 CO CONC2023/0004265A patent/CO2023004265A2/es unknown
- 2023-03-31 CL CL2023000961A patent/CL2023000961A1/es unknown
- 2023-03-31 EC ECSENADI202324034A patent/ECSP23024034A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023004265A2 (es) | 2023-04-27 |
CN116348486A (zh) | 2023-06-27 |
EP4222160A1 (en) | 2023-08-09 |
BR112023004871A2 (pt) | 2023-04-25 |
AU2021355518A9 (en) | 2024-02-08 |
EP4222159A1 (en) | 2023-08-09 |
CA3193722A1 (en) | 2022-04-07 |
JP2023544399A (ja) | 2023-10-23 |
MX2023003836A (es) | 2023-04-14 |
ECSP23024034A (es) | 2023-04-28 |
AU2021355521A1 (en) | 2023-05-11 |
AU2021355518A1 (en) | 2023-06-08 |
KR20230078748A (ko) | 2023-06-02 |
WO2022072934A1 (en) | 2022-04-07 |
US20230374063A1 (en) | 2023-11-23 |
CL2023000961A1 (es) | 2023-11-03 |
IL301572A (en) | 2023-05-01 |
KR20230061462A (ko) | 2023-05-08 |
AR123688A1 (es) | 2023-01-04 |
JP2023545019A (ja) | 2023-10-26 |
CA3192910A1 (en) | 2022-04-07 |
TW202229307A (zh) | 2022-08-01 |
PE20231507A1 (es) | 2023-09-26 |
CN116547292A (zh) | 2023-08-04 |
WO2022072919A1 (en) | 2022-04-07 |
IL301584A (en) | 2023-05-01 |
US20230406914A1 (en) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003863A (es) | Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped. | |
JP2003505343A (ja) | ボツリヌス神経毒を含む治療薬 | |
NZ527283A (en) | Modified antibodies and methods of use | |
JPH029394A (ja) | ヒトインターフエロンベーター2、その精製法及びその用途 | |
EP3325618B1 (en) | Novel trypsin isoforms and their use | |
AU2012311483B2 (en) | Combination therapy using immunoglobulin and C1-inhibitor | |
MX2009008843A (es) | Peptidomimeticos fijados a un patron. | |
CA3203208A1 (en) | Multifunctional panax quinquefolius hydrolyzed peptide and preparation method and application thereof | |
EP1349572B1 (en) | Manufacturing method of combined vaccine | |
Nagamatsu et al. | Purification and characterization of mouse α-lactalbumin and preparation of its antibody | |
CN112679589B (zh) | 一种多肽片段d及其应用 | |
JP2008506384A (ja) | 組換えα−フェトプロテイン、その調製のための方法及び手段、それをベースとした組成物、及びその使用 | |
KR101853463B1 (ko) | 보툴리눔 독소의 정제 방법 | |
CN107058269B (zh) | 药用激肽原酶及其制备方法和应用 | |
CN115124591A (zh) | 钝顶螺旋藻藻蓝蛋白血管紧张素转化酶抑制肽及其制备方法和应用 | |
Gulevskyy et al. | CURRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION | |
JPS59155324A (ja) | ヒト尿中チオ−ルプロテア−ゼインヒビタ−を有効成分とする抗炎症剤及びその製造法 | |
EP3337499A1 (en) | Enzymatic fractions with anti-inflammatory activity | |
CA2938733C (en) | Ultrapure hypoallergenic solutions of sacrosidase | |
JP2015200659A (ja) | 局所筋麻痺効果を有する非拡散型ボツリヌス毒素とその精製方法 | |
WO2023113843A3 (en) | Borylated di-peptide amino acid compositions for use in boron neutron capture therapy and methods thereof | |
JP2002316943A (ja) | 抗ニキビ組成物及びそれを含有するニキビ用化粧料 | |
CA3242543A1 (en) | Borylated di-peptide amino acid compositions for use in boron neutron capture therapy and methods thereof | |
JP6840086B2 (ja) | 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント | |
WO2023154841A3 (en) | Sars-cov-2 neutralizing synthetic proteins |